{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:34:42Z","timestamp":1778394882808,"version":"3.51.4"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,15]]},"DOI":"10.2146\/ajhp160934","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T10:40:13Z","timestamp":1496918413000},"page":"875-887","source":"Crossref","is-referenced-by-count":31,"title":["Solithromycin: A novel ketolide antibiotic"],"prefix":"10.1093","volume":"74","author":[{"given":"Michael J.","family":"Buege","sequence":"first","affiliation":[{"name":"Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack E.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY"},{"name":"Wegmans School of Pharmacy at St. John Fisher College, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel L.","family":"Aitken","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103222508000_b1-0740875","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/thoraxjnl-2015-207688","article-title":"Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998\u20132014","volume":"71","author":"Quan","year":"2016","journal-title":"Thorax"},{"key":"key\n\t\t\t\t2019041103222508000_b2-0740875","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1378\/chest.11-1160","article-title":"Incidence and cost of pneumonia in Medicare beneficiaries","volume":"142","author":"Thomas","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041103222508000_b3-0740875","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"key\n\t\t\t\t2019041103222508000_b4-0740875","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/425615","article-title":"The burden of community-acquired pneumonia in seniors: results of a population-based study","volume":"39","author":"Jackson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b5-0740875","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1164\/ajrccm.165.6.2103038","article-title":"Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States","volume":"165","author":"Kaplan","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t2019041103222508000_b6-0740875","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/j.1532-5415.2012.04208.x","article-title":"Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population","volume":"60","author":"Yu","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t2019041103222508000_b7-0740875","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cid\/ciu247","article-title":"Rates and risk factors for recurrent pneumonia in patients hospitalized with community-acquired pneumonia: population-based prospective cohort study with 5 years of follow-up","volume":"59","author":"Dang","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b8-0740875","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041103222508000_b9-0740875","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.123.5.1503","article-title":"Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database","volume":"123","author":"Brown","year":"2003","journal-title":"Chest"},{"issue":"suppl 2","key":"key\n\t\t\t\t2019041103222508000_b10-0740875","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b11-0740875","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMcp1214869","article-title":"Clinical practice. Community-acquired pneumonia","volume":"370","author":"Wunderink","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103222508000_b12-0740875","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b13-0740875","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"Metersky","year":"2007","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041103222508000_b14-0740875","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t2019041103222508000_b15-0740875","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1164\/rccm.201502-0212OC","article-title":"The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia","volume":"191","author":"Cilloniz","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t2019041103222508000_b16-0740875","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/324626","article-title":"Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications","volume":"34","author":"Leclercq","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b17-0740875","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/380126","article-title":"The clinical significance of macrolide-resistant Streptococcus pneumoniae: it\u2019s all relative","volume":"38","author":"Nuermberger","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b18-0740875","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"key\n\t\t\t\t2019041103222508000_b19-0740875","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MCP.0000000000000052","article-title":"Community-acquired pneumonia","volume":"20","author":"Remington","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"key\n\t\t\t\t2019041103222508000_b20-0740875","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1093\/jac\/dku207","article-title":"Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data","volume":"69","author":"Zhanel","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b21-0740875","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1128\/AAC.00185-16","article-title":"Results from the Solithromycin International Surveillance Program (2014)","volume":"60","author":"Farrell","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b22-0740875","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/652237","article-title":"The 10 \u00d7 \u201820 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020","volume":"50","author":"Infectious Diseases Society of America","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b23-0740875","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrd.2016.155","article-title":"Accelerating global innovation to address antibacterial resistance: introducing CARB-X","volume":"15","author":"Outterson","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019041103222508000_b24-0740875","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2174\/1568026033452159","article-title":"Macrolide antibiotics: binding site, mechanism of action, resistance","volume":"3","author":"Gaynor","year":"2003","journal-title":"Curr Top Med Chem"},{"key":"key\n\t\t\t\t2019041103222508000_b25-0740875","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0024-3205(67)90287-1","article-title":"Binding to ribosomes and inhibitory effect on protein synthesis of the spiramycin antibiotics","volume":"6","author":"Vazquez","year":"1967","journal-title":"Life Sci"},{"key":"key\n\t\t\t\t2019041103222508000_b26-0740875","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.1073\/pnas.1512090112","article-title":"Resistance to ketolide antibiotics by coordinated expression of rRNA methyltransferases in a bacterial producer of natural ketolides","volume":"112","author":"Almutairi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t2019041103222508000_b27-0740875","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.39.3.577","article-title":"Erythromycin resistance by ribosome modification","volume":"39","author":"Weisblum","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b28-0740875","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.44.8.2118-2125.2000","article-title":"Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage","volume":"44","author":"Tait-Kamradt","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b29-0740875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.45.1.1-12.2001","article-title":"Macrolide resistance conferred by base substitutions in 23S rRNA","volume":"45","author":"Vester","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b30-0740875","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1365-2958.1990.tb00696.x","article-title":"Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family","volume":"4","author":"Ross","year":"1990","journal-title":"Mol Microbiol"},{"key":"key\n\t\t\t\t2019041103222508000_b31-0740875","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1574-6968.1998.tb13232.x","article-title":"A plasmid that encodes three genes for resistance to macrolide antibiotics in Staphylococcus aureus","volume":"167","author":"Matsuoka","year":"1998","journal-title":"FEMS Microbiol Lett"},{"key":"key\n\t\t\t\t2019041103222508000_b32-0740875","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1469-0691.2000.00185.x","article-title":"Ketolides-telithromycin, an example of a new class of antibacterial agents","volume":"6","author":"Bryskier","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019041103222508000_b33-0740875","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2958.2000.01841.x","article-title":"Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA","volume":"36","author":"Douthwaite","year":"2000","journal-title":"Mol Microbiol"},{"key":"key\n\t\t\t\t2019041103222508000_b34-0740875","first-page":"140","article-title":"Macrolide antibiotic interaction and resistance on the bacterial ribosome","volume":"4","author":"Poehlsgaard","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041103222508000_b35-0740875","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nrmicro1265","article-title":"The bacterial ribosome as a target for antibiotics","volume":"3","author":"Poehlsgaard","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"key\n\t\t\t\t2019041103222508000_b36-0740875","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00860-10","article-title":"Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis","volume":"54","author":"Llano-Sotelo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b37-0740875","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1128\/AAC.00840-10","article-title":"Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors","volume":"54","author":"Bertrand","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b38-0740875","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.1016\/j.bmc.2016.08.035","article-title":"The solithromycin journey\u2014it is all in the chemistry","volume":"24","author":"Fernandes","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"key\n\t\t\t\t2019041103222508000_b39-0740875","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nature01321","article-title":"The inflammatory reflex","volume":"420","author":"Tracey","year":"2002","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041103222508000_b40-0740875","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature01339","article-title":"Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation","volume":"421","author":"Wang","year":"2003","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041103222508000_b41-0740875","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/AAC.01812-09","article-title":"Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection","volume":"54","author":"Biedenbach","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b42-0740875","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jinf.2010.08.010","article-title":"The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)","volume":"61","author":"Farrell","year":"2010","journal-title":"J Infect"},{"key":"key\n\t\t\t\t2019041103222508000_b43-0740875","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijantimicag.2010.01.026","article-title":"Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates","volume":"35","author":"Farrell","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041103222508000_b44-0740875","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/AAC.00036-12","article-title":"In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?","volume":"56","author":"Golparian","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b45-0740875","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1128\/AAC.01271-16","article-title":"In vitro activity of solithromycin against Bordetella pertussis - an emerging respiratory pathogen","volume":"60","author":"Hardy","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b46-0740875","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1128\/AAC.01639-13","article-title":"Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1","volume":"58","author":"Mallegol","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b47-0740875","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1128\/AAC.00564-13","article-title":"Determination of in vitro activity of solithromycin at different pHs and its intracellular activity tested against clinical isolates of Neisseria gonorrhoeae from a laboratory collection","volume":"57","author":"Mallegol","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b48-0740875","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2334-13-40","article-title":"Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011","volume":"13","author":"Olsen","year":"2013","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b49-0740875","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bmcl.2010.10.091","article-title":"Synthesis and antibacterial activity of novel 4-aryl-[1,2,3]-triazole containing macrolides","volume":"21","author":"Pereira","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t2019041103222508000_b50-0740875","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.diagmicrobio.2009.10.013","article-title":"CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of gram-positive and gram-negative bacteria","volume":"66","author":"Putnam","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b51-0740875","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijantimicag.2010.08.021","article-title":"Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci","volume":"37","author":"Putnam","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041103222508000_b52-0740875","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1128\/AAC.01343-09","article-title":"In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae","volume":"54","author":"Roblin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b53-0740875","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/jac\/dkv032","article-title":"Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms","volume":"70","author":"Vandevelde","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b54-0740875","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/AAC.00090-09","article-title":"Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101","volume":"53","author":"Waites","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b55-0740875","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.anaerobe.2016.10.002","article-title":"In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota","volume":"42","author":"Weintraub","year":"2016","journal-title":"Anaerobe"},{"key":"key\n\t\t\t\t2019041103222508000_b56-0740875","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1128\/AAC.02210-13","article-title":"In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae","volume":"58","author":"Piccinelli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b57-0740875","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1128\/AAC.04568-14","article-title":"Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012","volume":"59","author":"Farrell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b58-0740875","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/AAC.01123-09","article-title":"In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms","volume":"54","author":"McGhee","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b59-0740875","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/AAC.02411-14","article-title":"In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains","volume":"58","author":"Jensen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b60-0740875","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/AAC.05039-11","article-title":"In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species","volume":"56","author":"Wittlin","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b61-0740875","unstructured":"Food and Drug Administration. Briefing document. Solithromycin oral capsule and injection. Meeting of the Antimicrobial Drugs Advisory Committee (November04, 2016). www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM527690.pdf (accessed 2016 Nov 5)."},{"key":"key\n\t\t\t\t2019041103222508000_b62-0740875","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1128\/AAC.00863-16","article-title":"Efficacy of solithromycin (CEM-101) for experimental otitis media caused by nontypeable Haemophilus influenzae and Streptococcus pneumoniae","volume":"60","author":"Figueira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b63-0740875","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1128\/AAC.01429-10","article-title":"Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects","volume":"55","author":"Still","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b64-0740875","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1128\/AAC.00766-12","article-title":"Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects","volume":"56","author":"Rodvold","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b65-0740875","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1128\/AAC.02561-15","article-title":"Solithromycin pharmacokinetics in plasma and dried blood spots and safety in adolescents","volume":"60","author":"Gonzalez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b66-0740875","unstructured":"ClinicalTrials.gov. Pharmacokinetics and safety of solithromycin in adolescents and children (NCT02268279). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268279 (accessed 2017 Mar 8)."},{"key":"key\n\t\t\t\t2019041103222508000_b67-0740875","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/AAC.01743-13","article-title":"Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model","volume":"58","author":"Keelan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b68-0740875","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1128\/AAC.03187-14","article-title":"Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection","volume":"58","author":"Miura","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b69-0740875","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.placenta.2014.09.009","article-title":"Transplacental passage and anti-inflammatory effects of solithromycin in the human placenta","volume":"35","author":"Keelan","year":"2014","journal-title":"Placenta"},{"key":"key\n\t\t\t\t2019041103222508000_b70-0740875","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.04652-14","article-title":"Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment","volume":"59","author":"Jamieson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b71-0740875","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/106002809202600112","article-title":"The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin","volume":"26","author":"Bahal","year":"1992","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041103222508000_b72-0740875","first-page":"211","article-title":"Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture","volume":"16","author":"Carlier","year":"1994","journal-title":"Int J Tissue React"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041103222508000_b73-0740875","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0924-8579(01)00406-X","article-title":"Macrolides: pharmacokinetics and pharmacodynamics","volume":"18","author":"Van Bambeke","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041103222508000_b74-0740875","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1128\/AAC.00203-09","article-title":"Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages","volume":"53","author":"Lemaire","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl B","key":"key\n\t\t\t\t2019041103222508000_b75-0740875","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/20.suppl_B.47","article-title":"Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells","volume":"20","author":"Carlier","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b76-0740875","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/AAC.00197-13","article-title":"Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia","volume":"57","author":"Oldach","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b77-0740875","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIREORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b78-0740875","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multi-center study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b79-0740875","unstructured":"Food and Drug Administration. Briefing document: endpoints and clinical trial issues in community-acquired bacterial pneumonia. Anti-Infective Drugs Advisory Committee (November03, 2011). www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/anti-infectivedrugsadvisorycommittee\/ucm275823.pdf (accessed 2016 Nov 5)."},{"key":"key\n\t\t\t\t2019041103222508000_b80-0740875","unstructured":"ClinicalTrials.gov. Safety and efficacy of solithromycin in adolescents and children with community-acquired bacterial pneumonia (NCT02605122). https:\/\/clinicaltrials.gov\/ct2\/results?term=NCT02605122 (accessed 2017 Mar 8)."},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041103222508000_b81-0740875","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0016-5085(14)60517-5","article-title":"Anti-NASH effects of solithromycin in NASH-HCC mouse model","volume":"146","author":"Fernandes","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019041103222508000_b82-0740875","unstructured":"ClinicalTrials.gov. Safety and efficacy of solithromycin in the treatment of nonalcoholic steatohepatitis without cirrhosis (NCT02510599). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02510599?term=NCT02510599 (accessed 2017 Mar 8)."},{"key":"key\n\t\t\t\t2019041103222508000_b83-0740875","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/cid\/civ478","article-title":"A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea","volume":"61","author":"Hook","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b84-0740875","unstructured":"ClinicalTrials.gov. Genitourinary and pharyngeal pharmacokinetics of solithromycin (NCT02348424). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02348424 (accessed 2017 Mar 8)."},{"key":"key\n\t\t\t\t2019041103222508000_b85-0740875","unstructured":"ClinicalTrials.gov. Efficacy and safety study of oral solithromycin compared to intramuscular ceftriaxone plus oral azithromycin in the treatment of patients with gonorrhea (NCT02210325). https:\/\/clinicaltrials.gov\/ct2\/results?term=NCT02210325 (accessed 2017 Mar 8)."},{"key":"key\n\t\t\t\t2019041103222508000_b86-0740875","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1365-2222.2012.03979.x","article-title":"Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments","volume":"42","author":"Cameron","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"key\n\t\t\t\t2019041103222508000_b87-0740875","unstructured":"ClinicalTrials.gov. A study to evaluate the anti-inflammatory effects of solithromycin in chronic obstructive pulmonary disease (NCT02628769). https:\/\/clinicaltrials.gov\/ct2\/results?term=NCT02628769 (accessed 2017 Mar 8)."},{"key":"key\n\t\t\t\t2019041103222508000_b88-0740875","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1755-5922.12054","article-title":"Antibiotic-induced cardiac arrhythmias","volume":"32","author":"Abo-Salem","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"key\n\t\t\t\t2019041103222508000_b89-0740875","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkw428","article-title":"Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects","volume":"72","author":"Darpo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b90-0740875","unstructured":"Cempra. Cempra receives complete response letter from FDA for solithromycin NDAs (December29, 2016). http:\/\/investor.cempra.com\/releasedetail.cfm?ReleaseID=1005708 (accessed 2017 Feb 17)."},{"key":"key\n\t\t\t\t2019041103222508000_b91-0740875","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"key\n\t\t\t\t2019041103222508000_b92-0740875","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Mathers Dunbar","year":"2004","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041103222508000_b93-0740875","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/00365540110077443","article-title":"Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis\/tonsillitis","volume":"33","author":"Norrby","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t2019041103222508000_b94-0740875","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t2019041103222508000_b95-0740875","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0149-2918(03)80087-5","article-title":"Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis\/pharyngitis: a multicenter, randomized, double-blind, parallel-group study","volume":"25","author":"Quinn","year":"2003","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041103222508000_b96-0740875","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/147323000303100301","article-title":"Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis","volume":"31","author":"Zervos","year":"2003","journal-title":"J Int Med Res"},{"key":"key\n\t\t\t\t2019041103222508000_b97-0740875","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103222508000_b98-0740875","unstructured":"Food and Drug Administration. Telithromycin (marketed as Ketek) information. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafety-InformationforPatientsandProviders\/ucm107824.htm (accessed 2016 Nov 5)."},{"key":"key\n\t\t\t\t2019041103222508000_b99-0740875","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jama.2013.280318","article-title":"Conjunctivitis: a systematic review of diagnosis and treatment","volume":"310","author":"Azari","year":"2013","journal-title":"JAMA"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/12\/875\/28336047\/ajhp0875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T23:30:17Z","timestamp":1692833417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/12\/875\/5102528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,6,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160934","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6,15]]},"published":{"date-parts":[[2017,6,15]]}}}